Contact Us
Drug Search Results
More Filters [+]

Ladarixin

Alternative Names: ladarixin, df-2156a, df 2156a, df2156a
Latest Update: 2024-12-19
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: CXCR1 Antagonist,CXCR2 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Dompe
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ladarixin

Countries in Clinic: Belgium, Georgia, Germany, Israel, Italy, Serbia, Slovenia, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 2: Obesity|Overweight|Type 1 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
LDX0319

P2

Unknown Status

Type 1 Diabetes

2026-03-25

GLADIATOR

P2

Active, not recruiting

Type 1 Diabetes

2024-04-05

2022-000743-68

P2

Active, not recruiting

Overweight|Type 1 Diabetes

2023-08-19

Ladarixin in obese pre-diabetic patients eligible to bariatric surgery

P2

Active, not recruiting

Obesity

2022-02-11

Recent News Events

Date

Type

Title

10/01/2023

PubMed

 The therapeutic potential of an allosteric non-competitive CXCR1/2 antagonist for diabetic nephropathy.

07/11/2023

News Article

 Less than half of endocrinologists are impressed with Tzield's ability to delay T1D (MARKETVUE® REPORT)

06/20/2023

PubMed

 Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders.

01/15/2023

PubMed

 Stress-related testicular changes in Wistar and Sprague-Dawley rats following oral administration of an interleukin-8 inhibitor.

11/26/2021

News Article

 Global Diabetes Pipeline Landscape Insights Report, 2021 - Featuring Emerging Drugs Tirzepatide, ORMD-0801, Ladarixin, Enavogliflozin, and DBPR-108

06/15/2020

News Article

 Dompé Presents Phase II Clinical Trial Results for Ladarixin in New-Onset Type 1 Diabetes at the American Diabetes Association's Scientific Sessions

06/15/2020

News Article

 Dompé Presents Phase II Clinical Trial Results for Ladarixin in New-Onset Type 1 Diabetes at the American Diabetes Association's Scientific Sessions

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions